

Financial news for ABBV dated on 2020-06-10: AbbVie And Genmab Announce Broad Oncology Collaboration; AbbVie To Pay Genmab \$750M Up Front As Well As Potential Milestones Of Up To \$3.15B

Financial news for ABBV dated on 2020-06-08: AbbVie On Saturday Presents Data Showing RINVOQ Met Its Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in Rheumatoid Arthritis Patients

Financial news for ABBV dated on 2020-06-04: AbbVie Highlights Presentation Of New Long-Term Data From RINVOQ Phase 3 Studies At 2020 Annual European E-Congress Of Rheumatology

Financial news for ABBV dated on 2020-06-02: Argus Research Upgrades AbbVie to Buy, Announces \$115 Price Target

Financial news for ABBV dated on 2020-06-01: AbbVie Reports Submission Of Regulatory Applications To FDA, EMA For RINVOQ For Treatment Of Adults With Active Psoriatic Arthritis

Financial news for ABBV dated on 2020-06-01: AbbVie and Jacobio Earlier Announced a Strategic Collaboration to Advance SHP2 Inhibitors

Financial news for ABBV dated on 2020-05-27: AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio

Financial news for ABBV dated on 2020-05-27: Ironwood And AbbVie Report Phase II Trial Of MD-7246 Did Not Achieve Statistically Significant Improvements In Abdominal Pain Relative To Placebo, Companies Plan To Discontinue Development

Financial news for ABBV dated on 2020-05-21: Synlogic Terminates Collaboration Deal With AbbVie

Financial news for ABBV dated on 2020-05-18: B of A Securities Reinstates Neutral on AbbVie, Announces \$95 Price Target

Financial news for ABBV dated on 2020-05-14: AbbVie Shares Rebound From Session Low As CEO Recently Spoke With Jim Cramer On CNBC's Squawk Street

Financial news for ABBV dated on 2020-05-12: AbbVie shares are trading higher JP Morgan upgraded the stock from Neutral to Overweight.

Financial news for ABBV dated on 2020-05-12: JP Morgan Upgrades AbbVie to Overweight

Financial news for ABBV dated on 2020-05-11: UPDATE: Morgan Stanley On Abbvie Notes 'This is an earnings and multiple call, and we see a positive risk-reward skew given ABBV's 5.6% dividend yield'

Financial news for ABBV dated on 2020-05-11: UPDATE: Morgan Stanley Reinstates Abbvie With Overweight, \$95 Target Notes 'We view Humira erosion fears as overly discounted and Abbvie's prospects as underappreciated'

Financial news for ABBV dated on 2020-05-11: Morgan Stanley Reinstates Overweight on AbbVie, Announces \$95 Price Target

Financial news for ABBV dated on 2020-05-11: SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to \$122

Financial news for ABBV dated on 2020-05-05: AbbVie, Allergan Report FTC Clearance For Deal

Financial news for ABBV dated on 2020-05-05: Abbvie Purchase Of Allergan FTC Approval Is Imminent, Mlex Says

Financial news for ABBV dated on 2020-05-05: AbbVie shares are trading higher after the company received Health Canada approval for the combination of VENCLEXTA with Obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.

Financial news for ABBV dated on 2020-05-05: AbbVie Receives Health Canada Approval For The Combination Of VENCLEXTA With Obinutuzumab For Patients With Previously Untreated Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2020-05-04: SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to \$107

Financial news for ABBV dated on 2020-05-01: From AbbVie Earnings Conference Call: Sees FY20 US Humira Sales Up ~7%

Financial news for ABBV dated on 2020-05-01: AbbVie Reaffirms FY20 Standalone Adj.

EPS Guidance \$9.61-\$9.71

Financial news for ABBV dated on 2020-05-01: AbbVie Q1 Adj. EPS \$2.420 Beats \$2.250 Estimate, Sales \$8.619B Beat \$8.330B Estimate

Financial news for ABBV dated on 2020-04-27: Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma, Triggering a \$50M Milestone Payment from AbbVie

Financial news for ABBV dated on 2020-04-21: FDA Says Expanded The Indication Of Ibrutinib (Imbruvica)

Financial news for ABBV dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for ABBV dated on 2020-04-20: RBC Capital Upgrades AbbVie to Outperform, Raises Price Target to \$93

Financial news for ABBV dated on 2020-04-13: UBS Maintains Buy on AbbVie, Lowers Price Target to \$96

Financial news for ABBV dated on 2020-03-31: Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has potentially benefited the sector due to demand for medical supplies, testing and treatment candidates

Financial news for ABBV dated on 2020-03-23: AbbVie's Phase 3 Trial of VENCLEXTA in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia Met its Dual Primary Endpoints

Financial news for ABBV dated on 2020-03-23: Societe Generale Downgrades AbbVie to Hold

Financial news for ABBV dated on 2020-03-17: AbbVie, Allergan Report Signing Of Consent Decree Deal With FTC Staff Related To Deal

Financial news for ABBV dated on 2020-03-12: AbbVie Reports European Commission Approval Of VENCLYXTO Combo Regimen For Patients With Previously-Untreated Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2020-03-11: Abbvie Announces New Formulary Listings For Skyrizi In The Treatment Of Moderate To Severe Plaque Psoriasis; Manitoba Lists Skyrizi On Its Provincial Formulary Effective Mar 02, Non-Insured Health Benefits Program Lists Skyrizi On Its Formulary

Financial news for ABBV dated on 2020-03-09: Abbvie Says Partnering With Global Authorities To Determine Efficacy Of HIV Drug In Treating COVID-19

Financial news for ABBV dated on 2020-03-09: Bristol Myers' Phase 3 Trial of Empliciti in Untreated Multiple Myeloma Did Not Meet its Primary Endpoint

Financial news for ABBV dated on 2020-03-03: AbbVie, Allergan Receive Final European Approval To Close Deal

Financial news for ABBV dated on 2020-03-02: AbbVie Earlier Reported Results From Phase 3 Study Evaluating VENCLEXTA Did Not Meet Primary Endpoint Of Statistically Significant Improvement Of Overall Survival For Patients With Acute Myeloid Leukemia

Financial news for ABBV dated on 2020-02-27: Barclays Initiates Coverage On AbbVie with Equal-Weight Rating, Announces \$97 Price Target

Financial news for ABBV dated on 2020-02-19: AbbVie to Present at the Cowen 40th Annual Health Care Conference On March 4, 2020

Financial news for ABBV dated on 2020-02-18: Cowen & Co. Maintains Outperform on AbbVie, Raises Price Target to \$105

Financial news for ABBV dated on 2020-02-10: AbbVie shares are trading higher after Mizuho maintained a Buy rating on the stock and raised its price target from \$96 to \$104.

Financial news for ABBV dated on 2020-02-10: Mizuho Maintains Buy on AbbVie, Raises Price Target to \$104

Financial news for ABBV dated on 2020-02-07: From AbbVie Earnings Conference Call: CFO Sees US Humira Sales Up 9% This Year

Financial news for ABBV dated on 2020-02-07: From AbbVie Earnings Conference Call: Commercial Access For RINVOQ At 95+%, For SKYRIZI At Parity To Humira, 95+%

Financial news for ABBV dated on 2020-02-07: AbbVie shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY20 EPS guidance above analyst estimates and sales growth of ~8%.

Financial news for ABBV dated on 2020-02-07: AbbVie Sees FY20 Adj. EPS \$9.61-\$9.71 vs \$9.48 Estimate, Sales Growth ~8%

Financial news for ABBV dated on 2020-02-07: AbbVie Q4 EPS \$2.21 Beats \$2.19 Estimate, Sales \$8.704B Beat \$8.7B Estimate

Financial news for ABBV dated on 2020-02-06: UPDATE: Mizuho Initiates Coverage On AbbVie with Buy Rating, Announces \$96 Price Target As Firm Notes The 'Allergan Acquisition Brings In Multiple New Growth Drivers and Helps Mitigate Humira Erosion.'

Financial news for ABBV dated on 2020-02-06: Mizuho Initiates Coverage On AbbVie with Buy Rating, Announces \$96 Price Target

Financial news for ABBV dated on 2020-02-05: Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings

Financial news for ABBV dated on 2020-02-05: AbbVie Announces RINVOQ Met Primary And Key Secondary Endpoints In Phase 3 Study In Psoriatic Arthritis

Financial news for ABBV dated on 2020-01-31: AbbVie Reports Receives Positive CHMP Opinion For Maviret For Chronic Hep C, Compensated Cirrhosis

Financial news for ABBV dated on 2020-01-31: AbbVie Reports Receives Positive CHMP Opinion For VENCLYXTO For Chemo-Free Combo Regimen For Patients With Previously-Untreated Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2020-01-27: AbbVie shares are trading higher after the company announced Allergan entered into definitive agreements to divest brazikumab and Zenpep. The agreements are apart of the approval process for AbbVie's acquisition of Allergan.

Financial news for ABBV dated on 2020-01-27: 'China testing HIV drug as treatment for new coronavirus, AbbVie says' -Reuters

Financial news for ABBV dated on 2020-01-15: From JP Morgan Healthcare Conference: AbbVie CEO Sees 7-8 US Competitors To Humira In 2023

Financial news for ABBV dated on 2020-01-15: From JP Morgan Healthcare Conference: AbbVie CEO Sees Humira Sales Starting To Slow Heading Into FY22

Financial news for ABBV dated on 2020-01-15: From JP Morgan Healthcare Conference: AbbVie CEO Sees Humira Continuing To Grow In US Through The Time It Loses Market Exclusivity

Financial news for ABBV dated on 2020-01-14: Abbvie's SKYRIZI Met Barth Primary And All Ranked Secondary Endpoints In Phase 3 Study

Financial news for ABBV dated on 2020-01-10: EU Commission Approves Abbvie's Acquisition Of Allergan, Subject To Conditions

Financial news for ABBV dated on 2020-01-07: AbbVie Receives Health Canada Approval Of RINVOQ, An Oral Medication For Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis

Financial news for ABBV dated on 2019-12-26: Cowen & Co. Maintains Outperform on AbbVie, Raises Price Target to \$98

Financial news for ABBV dated on 2019-12-20: AbbVie shares are trading higher. Not seeing any news to justify the price action.

Financial news for ABBV dated on 2019-12-18: Abbvie Reaches An Agreement With The Pan-Canadian Pharmaceutical Alliance For The Combination Venclexta With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2019-12-18: AbbVie Receives European Commission Approval Of RINVOQ For The Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis

Financial news for ABBV dated on 2019-12-13: Watching Allergan Shares AS Hearing Co. Deal With AbbVie To Receive US Regulatory Approval In Jan. 2020

Financial news for ABBV dated on 2019-12-09: AbbVie and Scripps Research to

## Collaborate on New Therapies

Financial news for ABBV dated on 2019-12-06: AbbVie Reports Deal With Pan-Canadian Pharma Alliance For Skyrizi For Treatment Of Moderate To Severe Plaque Psoriasis

Financial news for ABBV dated on 2019-12-02: U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada

Financial news for ABBV dated on 2019-11-22: Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are "MUCH CHEAPER"

Financial news for ABBV dated on 2019-11-20: Citi Maintains Buy on AbbVie, Raises Price Target to \$98

Financial news for ABBV dated on 2019-11-20: Dragonfly Therapeutics Announces Collaboration With AbbVie For Autoimmune Diseases and Oncology

Financial news for ABBV dated on 2019-11-19: UBS Maintains Buy on AbbVie, Raises Price Target to \$96

Financial news for ABBV dated on 2019-11-12: AbbVie shares are trading higher after the company announced its Phase 2/3 SELECT-AXIS1 trial in which twice as many adult patients with active ankylosing spondylitis treated with RINVOQ achieved the primary endpoint.

Financial news for ABBV dated on 2019-11-12: Abbvie Presents Data Showing RINVOQ Met Its Primary Endpoint

Financial news for ABBV dated on 2019-11-08: AbbVie shares are trading higher. The company submitted a Supplemental New Drug Application For IMBRUVICA. The company is also looking to raise as much as \$28 billion to fund its Allergan takeover.

Financial news for ABBV dated on 2019-11-08: AbbVie Reports Submission Of Supplemental New Drug Application For IMBRUVICA

Financial news for ABBV dated on 2019-11-06: AbbVie Announces Launch Of Private Offering Of Senior Unsecured Notes; Terms Not Disclosed

Financial news for ABBV dated on 2019-11-05: Allergan And Abbvie Continue To Expect To Close The Transaction In Early 2020

Financial news for ABBV dated on 2019-11-01: AbbVie shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised its FY19 EPS guidance above analyst estimates.

Financial news for ABBV dated on 2019-11-01: From AbbVie Earnings Conference Call: Co. Notified FTC It Plans To Divest 2 Assets For Allergan Deal To Go Through

Financial news for ABBV dated on 2019-11-01: Abbvie Sees 2019 Revenue Growth Of 2.5% On Operational Basis

Financial news for ABBV dated on 2019-11-01: Abbvie Says Launch Of Psoriasis Drug Skyrizi 'Is Going Extremely Well' And Commercial Access For The Drug Is At More Than 80%

Financial news for ABBV dated on 2019-11-01: AbbVie Narrows, Raises Lower End Of FY19 Adj. EPS Guidance From \$8.82-\$8.92 To \$8.90-\$8.92 vs \$8.90 Estimate

Financial news for ABBV dated on 2019-11-01: AbbVie Q3 Adj. EPS \$2.33 Beats \$2.3 Estimate, Sales \$8.479B Beat \$8.38B Estimate

Financial news for ABBV dated on 2019-10-31: Abbvie's RINVOQ Meets Primary And All Ranked Secondary Endpoints In Phase 3 Study In Psoriatic Arthritis

Financial news for ABBV dated on 2019-10-14: Allergan Reports Shareholders Have Approved Deal By AbbVie

Financial news for ABBV dated on 2019-10-01: AbbVie shares trading lower with the broader stock market following concerning ISM manufacturing data. Not seeing any company-specific news to justify the move lower.

Financial news for ABBV dated on 2019-09-27: Abbvie Inc Co And Allergan Are Cooperating Fully With FTC And Continue To Expect To Close Transaction In Early 2020

Financial news for ABBV dated on 2019-09-26: AbbVie shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.

Financial news for ABBV dated on 2019-09-26: Citigroup Upgrades AbbVie to Buy

Financial news for ABBV dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for ABBV dated on 2019-09-12: UPDATE: UBS On AbbVie Also Notes 'Post '23 we estimate stable cash flows driven by ABBV's 5 key growth assets & AGN Aesthetics franchise. NEWCO cash flows are immediately tangible via a sustainable & growing dividend'

Financial news for ABBV dated on 2019-09-12: UPDATE: UBS Upgrades AbbVie To Buy, Lowers Target To \$79 As Firm Notes Co's 'acquisition of AGN leads to a NEWCO generating \$20B+ of annual free cash flow growing to a highly compelling, 9% FCF yield in '23E (year of Humira's US patent expiry)'

Financial news for ABBV dated on 2019-09-12: AbbVie shares are trading higher after UBS upgraded the stock from Neutral to Buy.

Financial news for ABBV dated on 2019-09-12: UBS Upgrades AbbVie to Buy, Lowers Price Target to \$79

Financial news for ABBV dated on 2019-09-04: Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration With AbbVie

Financial news for ABBV dated on 2019-09-04: Piper Jaffray Maintains Overweight on AbbVie, Raises Price Target to \$81

Financial news for ABBV dated on 2019-08-29: AbbVie Says its Phase 3 Trial Evaluating Rova-T Demonstrated 'No Survival Benefit'

Financial news for ABBV dated on 2019-08-29: AbbVie to Discontinue Development of Rovalpituzumab Tesirine (Rova-T)

Financial news for ABBV dated on 2019-08-20: UPDATE: PiperJaffray On AbbVie Also Notes 'while we have been rather vocal about the various pressure points on the Humira business, we do think ABBV has a great opportunity to pivot the narrative towards successful launches of Skyrizi and now Rinvoq'

Financial news for ABBV dated on 2019-08-20: UPDATE: PiperJaffray Upgrades AbbVie To Overweight, Announces \$80 Target As Firm Notes 'we do think a bottom of sorts has been found on this name with the stock around ~\$66'

Financial news for ABBV dated on 2019-08-20: AbbVie shares are trading higher after Piper Jaffray upgraded the stock from Neutral to Overweight and announced a price target of \$80 per share.

Financial news for ABBV dated on 2019-08-20: Piper Jaffray Upgrades AbbVie to Overweight, Announces \$80 Price Target

Financial news for ABBV dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for ABBV dated on 2019-08-16: FDA Approves Nda For Abbvie's Rinvoq (Upadacitinib) For Treatment Of Rheumatoid Arthritis

Financial news for ABBV dated on 2019-08-07: AbbVie Shares Tick Slightly Lower As Hearing Co. Accused Of Scheming To Stretch Androgel Monopoly

Financial news for ABBV dated on 2019-08-05: AbbVie Submits New Drug Application FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

Financial news for ABBV dated on 2019-08-02: Enanta's HCV Collaboration Partner AbbVie Receives Approval By European Commission For MAVIRET To Shorten Treatment Duration To Eight Weeks For Treatment-Naive HCV Patients With Compensated Cirrhosis

Financial news for ABBV dated on 2019-07-26: From AbbVie Q2 Earnings Conference Call: Raises FY19 Sales Growth Guidance From ~1% To ~2%

Financial news for ABBV dated on 2019-07-26: Abbvie CEO Says Co Remains 'Well Positioned' To Deliver Double-Digit Earnings Growth In 2019

Financial news for ABBV dated on 2019-07-26: AbbVie shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised its FY19 EPS guidance above analyst estimates.

Financial news for ABBV dated on 2019-07-26: UPDATE: AbbVie Raises FY19 Adj EPS

Guidance From \$8.73-\$8.83 To \$8.82-\$8.92 vs \$8.82 Estimate

Financial news for ABBV dated on 2019-07-26: AbbVie Raises FY19 Guidance

Financial news for ABBV dated on 2019-07-26: AbbVie Q2 Adj. EPS \$2.26 Beats \$2.2 Estimate, Sales \$8.255B Beat \$8.1B Estimate

Financial news for ABBV dated on 2019-07-15: AbbVie Acquires Mavupharma; Terms Not Disclosed

Financial news for ABBV dated on 2019-07-09: CytomX Therapeutics Announces Second Target Selection And Program Initiation With AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration

Financial news for ABBV dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay for prescription drugs.

Financial news for ABBV dated on 2019-06-28: AbbVie Shares Tick Higher Over Last Few Mins. Following Mention Of Unusual Option Activity By Jon Najarian On CNBC's 'Fast Money: Halftime Report'

Financial news for ABBV dated on 2019-06-28: AbbVie shares are trading higher as the stock continues to rebound after dipping on Tuesday when the company announced it will acquire Allergan for \$60 billion.

Financial news for ABBV dated on 2019-06-27: AbbVie shares are trading higher as the stock continues to rebound after dipping on Tuesday when the company announced it will acquire Allergan for \$60 billion.

Financial news for ABBV dated on 2019-06-26: AbbVie shares are trading higher, rebounding after dipping on Monday following the announcement that the company will acquire Allergan for \$60 billion. SVB Leerink upgraded the stock from Market Perform to Outperform.

Financial news for ABBV dated on 2019-06-26: SVB Leerink Upgrades AbbVie to Outperform

Financial news for ABBV dated on 2019-06-25: AbbVie Receives Positive Recommendation From INESSS For The Combination VENCLEXTA With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2019-06-25: AbbVie CEO Says Feels Comfortable With Risk Related To Allergan's Opioid Exposure

Financial news for ABBV dated on 2019-06-25: AbbVie CEO Says Believes It Is Highly Unlikely There Will Be A Botox Biosimilar For A Long Time

Financial news for ABBV dated on 2019-06-25: AbbVie Says Allergan Deal Mitigates Impact Of 2023 US Humira Loss Of Exclusivity

Financial news for ABBV dated on 2019-06-25: AbbVie shares are trading lower after the company announced it will acquire Allergan for \$188.24/share.

Financial news for ABBV dated on 2019-06-25: AbbVie To Acquire Allergan For \$188.24/Share In Cash And Stock

Financial news for ABBV dated on 2019-06-25: UPDATE: AbbVie Would Pay \$188/Share In Cash And Stock For Allergan, Representing 45% Premium To Allergan's Monday Close, According To Sources Cited By WSJ

Financial news for ABBV dated on 2019-06-24: AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality

Financial news for ABBV dated on 2019-06-14: Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthritis at the European Congress of Rheumatology

Financial news for ABBV dated on 2019-06-12: AbbVie Reports To Present New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks at EULAR

Financial news for ABBV dated on 2019-06-11: AbbVie shares are trading higher after the company's SKYRIZI maintained its complete skin clearance.

Financial news for ABBV dated on 2019-06-06: AbbVie Reports Recommendation From Pan-Canadian Oncology Drug Review Expert Review Committee For Combo VENCLEXTA With

Rituximab As Treatment For Patients With Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2019-06-04: AbbVie Highlights Publication Of Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2019-05-30: AbbVie To Present Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings

Financial news for ABBV dated on 2019-05-28: Goldman Sachs Initiates Coverage On AbbVie with Neutral Rating, Announces \$84 Price Target

Financial news for ABBV dated on 2019-05-22: Trader Idea Feed: 'We took a look at the late-stage brain cancer pipeline, after \$TOCA news and \$ABBV and \$BMY failures this month. And found only 5 active pivotal trials. Which includes \$NWBO, so arguably only 4. Is \$CELG the next big hope?' @ByAmyBrown

Financial news for ABBV dated on 2019-05-17: AbbVie Reports Study On Depatuxizumab Mafodotin Did Not Meet Primary Endpoint

Financial news for ABBV dated on 2019-05-14: MC10 And AbbVie Announce Clinical Trials In Multiple Sclerosis Using The BioStamp nPoint System

Financial news for ABBV dated on 2019-05-14: AbbVie shares are trading higher after the company settled its HUMIRA patent litigation with Boehringer Ingelheim.

Financial news for ABBV dated on 2019-05-14: AbbVie Resolves HUMIRA US Patent Litigation With Boehringer Ingelheim; Co. Will Grant BI A Non-Exclusive License To HUMIRA-Related Intellectual Property In US

Financial news for ABBV dated on 2019-04-30: European Commission Approves Abbvie's SKYRIZI For Treatment Of Moderate To Severe Plaque Psoriasis

Financial news for ABBV dated on 2019-04-30: AbbVie Highlights Will Present New, Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting

Financial news for ABBV dated on 2019-04-29: BMO Capital Upgrades AbbVie Inc. Common Stock to Market Perform, Raises Price Target to \$79

Financial news for ABBV dated on 2019-04-25: Abbvie Says It Is Industry's Responsibility To Cover Some Drug Costs And Share Them With The Government To Make Them Affordable For Patients

Financial news for ABBV dated on 2019-04-25: From Abbvie Conference Call; Co. Says Humira Biosimilars From Biogen And Amgen In Europe Have Been The Most Aggressive In The Market So Far

Financial news for ABBV dated on 2019-04-25: AbbVie Raises FY19 Adj. EPS Guidance From \$8.65-\$8.75 To \$8.73-\$8.83 vs \$8.69 Est.

Financial news for ABBV dated on 2019-04-25: AbbVie Q1 Adj. EPS \$2.14 Beats \$2.05 Estimate, Sales \$7.83B Beat \$7.76B Estimate

Financial news for ABBV dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for ABBV dated on 2019-04-18: Watching AbbVie Shares As Health Canada Approved Skyrizi For Treatment Of Moderate to Severe Plaque Psoriasis

Financial news for ABBV dated on 2019-04-11: AbbVie's MAVIRET Now reimbursed In Quebec

Financial news for ABBV dated on 2019-04-04: AbbVie Reports New Formulary Listings For Hep C Treatment MAVIRET

Financial news for ABBV dated on 2019-04-02: AbbVie shares are trading higher after development partner Alector announced it is initiating a phase 1 trial to treat Alzheimer's Disease.

Financial news for ABBV dated on 2019-04-01: Alector Initiates Phase 1 Trial Of AL003 For Treatment Of Patients With Alzheimer's Disease

Financial news for ABBV dated on 2019-03-22: British Columbia, Canada's Pharmacare Lists AbbVie's Maviret On Its Formulary, Effective Mar. 21, 2019

Financial news for ABBV dated on 2019-03-21: FDA Issues Warning Related To Risks Associated With AbbVie's VENCLEXTA In Multiple Myeloma

Financial news for ABBV dated on 2019-03-19: UPDATE: AbbVie Says 'remains confident in the benefit/risk profile of venetoclax in those approved indications'

Financial news for ABBV dated on 2019-03-19: UPDATE: AbbVie Says 'partial clinical hold follows a review of data from the ongoing Phase 3 BELLINI trial (M14-031), a study in relapsed/refractory multiple myeloma, in which a higher proportion of deaths was observed in the venetoclax arm'

Financial news for ABBV dated on 2019-03-19: AbbVie Reports FDA Placed Partial Clinical Hold On All Trials Evaluating Venetoclax For Treatment Of Multiple Myeloma

Financial news for ABBV dated on 2019-03-11: Principia Biopharma Reacquires Rights To Oral Immunoproteasome Program

Financial news for ABBV dated on 2019-03-07: AbbVie Reports FDA Granted Fifth Breakthrough Therapy Designation For Tovenetoclax For Combo Use With Obinutuzumab

Financial news for ABBV dated on 2019-03-01: AbbVie Reports Received CHMP Position Opinion For SKYRIZI For Treatment Of Moderate To Severe Plaque Psoriasis

Financial news for ABBV dated on 2019-02-22: Abbvie And Voyager Earlier Announced Parkinson's Collaboration With AbbVie; Voyager Will Receive \$65M Upfront And Up To \$245M In Preclinical And Phase 1 Option Payments

Financial news for ABBV dated on 2019-02-22: Voyager Therapeutics And AbbVie Announce Collaboration To Develop Vectorized Antibodies For Parkinson's Disease And Other Synucleinopathies; Voyager To Receive \$65M Upfront And Up To \$245M In Preclinical Phase 1 Option Payments

Financial news for ABBV dated on 2019-02-20: Morgan Stanley Expects A Verdict On Amgen Vs. Sandoz Enbrel IP Litigation In 1Q19; Firm Estimates 'ABBV could be down 6-8% if the ruling is against Amgen, up 1-2% if it's for Amgen, and ~0% if there is a settlement'

Financial news for ABBV dated on 2019-02-20: AbbVie Reports HUMIRA Approved By Health Canada To Treat Pediatric Patients With Chronic Non-Infectious Anterior Uveitis

Financial news for ABBV dated on 2019-02-19: AbbVie Reports New Drug Application Accepted For Priority Review By FDA For Upadacitinib For Treatment Of Moderate To Severe Rheumatoid Arthritis

Financial news for ABBV dated on 2019-02-15: FDA Commissioner Scott Gottlieb Issues Statement On New Policy To Improve Access, Foster Price Competition For Drugs Which Face Inadequate Generic Competition; FDA To Advance Added Policies To Promote This Over Next Year

Financial news for ABBV dated on 2019-02-15: Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage

Financial news for ABBV dated on 2019-02-11: AbbVie to Collaborate with Teneobio to Develop and Commercialize an Immunotherapeutic for the Treatment of Multiple Myeloma

Financial news for ABBV dated on 2019-02-05: Neurocrine Biosciences Sees FY19 Sales Milestones Under AbbVie Deal \$20M; Ongoing SG&A, R&D Expenses Expected \$550M-\$600M

Financial news for ABBV dated on 2019-01-28: Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019

Financial news for ABBV dated on 2019-01-28: Abbvie shares are continuing lower following a large sell off Friday due to worse than expected Q4 EPS and revenue results.

Financial news for ABBV dated on 2019-01-28: AbbVie Announces FDA Approval of IMBRUVICA Plus Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Previously Untreated Patien

Financial news for ABBV dated on 2019-01-25: From AbbVie Q4 Earnings Conference Call: CEO Richard Gonzalez Says Rumors Of His Retirement Are False

Financial news for ABBV dated on 2019-01-25: From AbbVie Q4 Earnings Conference Call: Sees Q1 EPS \$2.05-\$2.07 vs \$2.03 Estimate, Sales \$7.7B vs \$8B Est.

Financial news for ABBV dated on 2019-01-25: AbbVie shares are trading lower after the company missed Q4 EPS and sales estimates.



Financial news for ABBV dated on 2019-01-25: From AbbVie Conference Call; Co. Says Humira Will Continue To Generate 'Strong Revenue', Driving Roughly \$1B Of Growth In 2019

Financial news for ABBV dated on 2019-01-25: UPDATE: Coherus Says License Period In US Begins Dec. 15, 2023; Coherus Will Pay Royalties To AbbVie, But Financial Terms Not Disclosed

Financial news for ABBV dated on 2019-01-25: Coherus BioSciences Reports Global Settlement With AbbVie Which Secures Rights To Commercialize CHS-1420

Financial news for ABBV dated on 2019-01-25: AbbVie Inc. Sees FY19 Adj. EPS \$8.65-\$8.75 vs \$8.71 Est.

Financial news for ABBV dated on 2019-01-23: UBS Assumes AbbVie at Neutral, Lowers Price Target To \$91

Financial news for ABBV dated on 2019-01-18: AbbVie Announces Phase 3 Study of Ibrutinib In Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint Of Improving Progression-Free Survival

Financial news for ABBV dated on 2019-01-14: Stocks Trading Ex Dividend For Mon., Jan. 14, 2019

Financial news for ABBV dated on 2019-01-11: Stocks That Will Be Trading Ex Dividend Mon., Jan. 14, 2019

Financial news for ABBV dated on 2019-01-09: AbbVie Exec Speaking At JP Morgan Healthcare Conference Says Sees Non-Humira Sales Growing To \$35B+ In 2025, Sees Mavyret Remaining A Strong Source Of Cash Flow Over Long-Term

Financial news for ABBV dated on 2019-01-03: AbbVie Reports Strategic Collaboration With Tizona Therapeutics To Develop First-In-Class Immunotherapy For Cancer Targeting CD39

Financial news for ABBV dated on 2019-01-03: Bank of America Downgrades AbbVie to Neutral

Financial news for ABBV dated on 2018-12-26: Standpoint Research Initiates Coverage On AbbVie with Buy Rating

Financial news for ABBV dated on 2018-12-24: AbbVie Announces a Partnership with Lupin to Develop an Oncology Drug, AbbVie to Make a \$30M Upfront Payment

Financial news for ABBV dated on 2018-12-20: AbbVie shares are trading up 3.1% after the company submitted a New Drug Application to the FDA and a Marketing Authorization Application to the EMA for Upadacitinib for Rheumatoid Arthritis.

Financial news for ABBV dated on 2018-12-20: AbbVie Submits New Drug Application FDA And Marketing Authorization Application To EMA For Upadacitinib For Rheumatoid Arthritis

Financial news for ABBV dated on 2018-12-17: AbbVie Announces Executive Leadership Changes

Financial news for ABBV dated on 2018-12-17: Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints

Financial news for ABBV dated on 2018-12-13: AbbVie Adds \$5B To Buyback

Financial news for ABBV dated on 2018-12-06: AbbVie On Wednesday Announced It Has Halted Its Phase 3 Trial Of Rova-T In Advanced Small-Cell Lung Cancer After An Independent Data Monitoring Committee Recommended Terminating Enrollment

Financial news for ABBV dated on 2018-12-03: AbbVie Reports IMBRUVICA Phase 3 Combination Data With Obinutuzumab Shows Significant Improvement In Progression-Free Survival Over Standard Chemotherapy Of Chlorambucil Plus Obinutuzumab In Lymphocytic Leukemia And Small Lymphocytic Lymphoma

Financial news for ABBV dated on 2018-11-30: AbbVie shares are trading up 3.4% after the company announced a global patent license with Pfizer for HUMIRA; Pfizer shares up 1.3%.

Financial news for ABBV dated on 2018-11-30: Pfizer Reaches a Global Agreement With AbbVie For Biosimilar To HUMIRA

Financial news for ABBV dated on 2018-11-21: AbbVie Receives US FDA Accelerated Approval For VENCLEXTA For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia

## Patients Ineligible For Intensive Chemotherapy

Financial news for ABBV dated on 2018-11-14: AbbVie Reports Presented Phase 3 Data Showing Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

Financial news for ABBV dated on 2018-11-13: AbbVie Reports MAVYRET Showed High Virologic Cure Rates In Treatment-Naive Hepatitis C Patients With Compensated Cirrhosis

Financial news for ABBV dated on 2018-11-06: AbbVie Announces HUMIRA Global Patent License With Momenta

Financial news for ABBV dated on 2018-11-06: Argus Maintains Buy on AbbVie, Lowers Price Target to \$115

Financial news for ABBV dated on 2018-11-06: Lannett Announces Expanded Agreement With Strategic Alliance Partner, HEC Pharm Group, To Distribute Two FDA-Approved Products

Financial news for ABBV dated on 2018-11-05: BMO Capital Maintains Underperform on AbbVie, Lowers Price Target to \$71

Financial news for ABBV dated on 2018-11-02: From AbbVie Conference Call: Co. Says Will Continue With A Very Similar Price For Humira In The US Next Year

Financial news for ABBV dated on 2018-11-02: From AbbVie Conference Call: Co. Says Continues To Expect 2018 Humira Sales Of Approximately \$13.7B+

Financial news for ABBV dated on 2018-11-02: From AbbVie Conference Call: Co. Says More Than Half Of Humira Sales In US Driven By Volume Growth

Financial news for ABBV dated on 2018-11-02: AbbVie Raises Quarterly Dividend From \$0.96 To \$1.07/Share

Financial news for ABBV dated on 2018-11-02: AbbVie Raises FY18 Adj. EPS Guidance From \$7.76-\$7.86 To \$7.90-\$7.92 vs \$7.88 Est.

Financial news for ABBV dated on 2018-11-02: AbbVie Q3 Adj. EPS \$2.14 Beats \$2.01 Estimate, Sales \$8.24B Beat \$8.22B Estimate

Financial news for ABBV dated on 2018-11-01: 'AbbVie offers a 'huge' discount on Humira to fend off European rivals' -STAT News' Adam Feuerstein Now Tweets Article From Wed. Afternoon

Financial news for ABBV dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for ABBV dated on 2018-10-31: AbbVie Offers Results From CLL14 Phase 3 Trial: Met Primary Endpoint Showing 'patients treated with venetoclax plus obinutuzumab had superior progression-free survival compared to patients treated with standard of care obinutuzumab plus chlorambucil'

Financial news for ABBV dated on 2018-10-26: US Justice Department Says Abbott Laboratories, Abbvie To Pay \$25M To Resolve Case Over Tricor Marketing

Financial news for ABBV dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for ABBV dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for ABBV dated on 2018-10-23: AbbVie Reports Upadacitinib Showed Improvements In Physical Function, Pain, Quality Of Life As Monotherapy In Patients with Rheumatoid Arthritis In Phase 3 Patients-Reported Outcomes Data

Financial news for ABBV dated on 2018-10-22: AbbVie Reports Upadacitinib Met Primary And All Ranked Secondary Endpoints In Ulcerative Colitis Patients

Financial news for ABBV dated on 2018-10-19: Mylan Launches Hulio, A Biosimilar To AbbVie's Humira, In Markets Across Europe

Financial news for ABBV dated on 2018-10-18: AbbVie Announces Global Resolution Of HUMIRA Patent Disputes With Fresenius Kabi; Agreements Provide Non-Exclusive License To Fresenius Kabi For HUMIRA-Related IP In US Effective Sept. 2023, Fresenius Acknowledges Abbvie's Intellectual Property For Humira

Financial news for ABBV dated on 2018-10-18: AbbVie And Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Financial news for ABBV dated on 2018-10-17: AbbVie Announces Supplemental New Drug Application Accepted For Priority Review By FDA for IMBRUVICA In Combination With Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2018-10-11: UPDATE: Sandoz Will Pay Royalties To AbbVie For Licensing HUMIRA Patents, Acknowledges Validity Of Licensed Patents

Financial news for ABBV dated on 2018-10-11: UPDATE: AbbVie Says License Period With Sandoz Will Begin Sep. 30, 2023 In US, 'will not be accelerated by the entry of companies who have already taken a license'

Financial news for ABBV dated on 2018-10-11: UPDATE: AbbVie Will Grant Sandoz Non-Exclusive License To Co.'s IP Related To HUMIRA

Financial news for ABBV dated on 2018-10-11: AbbVie Reports Global Resolution Of HUMIRA Patent Disputes With Sandoz

Financial news for ABBV dated on 2018-10-08: AbbVie To Present New Data For Upadacitinib and HUMIRA(r) (adalimumab) At 2018 ACR/ARHP Annual Meeting October 19-24

Financial news for ABBV dated on 2018-10-08: AbbVie Late Friday Announced Receipt Of Health Canada Approval For ORILISSA For The Treatment Pain Associated With Endometriosis

Financial news for ABBV dated on 2018-09-25: UPDATE: AbbVie Says Approval Is Based On Murano Phase 3 Clinical Trial Data; Study Showed Significant Improvement In Progression-Free Survival

Financial news for ABBV dated on 2018-09-25: AbbVie Receives Approval From Health Canada For Combination Of VENCLEXTA With Rituximab As A Treatment For Patients With Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2018-09-18: '\$abbv being sued today by California for price collusion. This the least of the problems. Wait until the government starts exploring the rapid and unjustifiable death rate from Humira tgt \$60' - Citron Research Tweets

Financial news for ABBV dated on 2018-09-18: UPDATE: California Dept. Of Insurance Commissioner Dave Jones Suit Against AbbVie Related To Illegal Kickbacks In Promoting Humira

Financial news for ABBV dated on 2018-09-18: Abbvie Shares Down ~1.3% As California Insurance Regulator Sues Co. Over Alleged Kickbacks

Financial news for ABBV dated on 2018-09-13: AbbVie Reports Longer-Term, Patient-Reported Outcomes Data For Upadacitinib Phase 2b Atopic Dermatitis Study: Patients 'showed continuous improvements in skin lesions and pruritus (itch) at week 32'

Financial news for ABBV dated on 2018-09-13: AbbVie Reports Patient-Reported Outcomes Data From 3 Pivotal Phase 3 Studies Of Risankizumab Showing Improvements In Health-Related Quality Of Life For Patients With Psoriasis

Financial news for ABBV dated on 2018-09-11: AbbVie Reports FDA Expanded Label For VENCLEXTA In Combo With Rituximab to Include Info About Patients With Previously-Trated Chronic Lymphocytic Leukemia Who Achieved Minimal Residual Disease Negativity In Phase 3 MURANO Trial

Financial news for ABBV dated on 2018-08-24: Geron Shares Remain Elevated, Up 28.3% With Some Attributing Upside To Johnson & Johnson Job Posting For a Strategic Pricing Manager For Imbruvica & Imetelstat, Drugs Its Partnered On With AbbVie and Geron, Respectively

Financial news for ABBV dated on 2018-08-22: UPDATE: AbbVie Says No New Safety Signals Identified

Financial news for ABBV dated on 2018-08-22: AbbVie Offers Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids: Showed Reduction In Heavy Menstrual Bleeding For Up To 12 Months

Financial news for ABBV dated on 2018-08-22: Argenx Announces Abbvie Has Exercised Its Exclusive Option to License Argx-115; Argenx Eligible to Receive up to \$625M in Milestone Payments

Financial news for ABBV dated on 2018-07-30: AbbVie Option Alert: Fri \$88.5 Puts Sweep (26) near the Ask: 653 @ \$0.614 vs 124 OI; Ref=\$89.76

Financial news for ABBV dated on 2018-07-27: AbbVie Option Alert: Fri \$92 Puts Sweep (11) near the Ask: 500 @ \$3.0 vs 3600 OI; Earnings 7/27 Before Open Ref=\$88.989

Financial news for ABBV dated on 2018-07-27: Abbvie On Conf. Call Says They Expect Intl. Humira Sales To Approach \$6.4B This Year

Financial news for ABBV dated on 2018-07-27: AbbVie Q2 EPS \$2 Beats \$1.97 Estimate, Sales \$8.258B Beat \$8.21B Estimate

Financial news for ABBV dated on 2018-07-24: Neurocrine Biosciences 8-K Highlights FDA Approval Of AbbVie's ORILISSA; Co. To Receive \$40M Event-Based Payment Made By AbbVie

Financial news for ABBV dated on 2018-07-24: AbbVie Reports Received FDA Approval For ORILISSA For Mgmt. Of Moderate To Severe Pain Associated With Endometriosis

Financial news for ABBV dated on 2018-07-20: AbbVie Option Alert: Sep 21 \$85 Puts Sweep (21) near the Ask: 750 @ \$3.151 vs 1765 OI; Earnings 7/27 Before Open Ref=\$86.985

Financial news for ABBV dated on 2018-07-20: Adam Feuerstein, Responding To A Tweet That Citron Will Have More Abbvie Reports Out Soon, Tweets 'This promotional front-running nonsense erodes credibility.' (2/2)

Financial news for ABBV dated on 2018-07-20: Adam Feuerstein, Responding To A Tweet That Citron Will Have More Abbvie Reports Out Soon, Tweets 'In lieu of actual reports or information, let's just hype-tweet the threat of reports. If you have information, put it out there.' (1/2)

Financial news for ABBV dated on 2018-07-19: AbbVie Option Alert: Aug 17 \$87.5 Puts at the Ask: 800 @ \$2.3 vs 2213 OI; Earnings 7/27 Before Open Ref=\$89.725

Financial news for ABBV dated on 2018-07-19: 'Is there something about \$ABBV and the Humira patents...that the market doesn't already know about? Or is @CitronResearch just going to huff and puff the stock lower?' - STAT News' Adam F Tweets

Financial news for ABBV dated on 2018-07-17: UPDATE: AbbVie Will Make No Payments To Mylan

Financial news for ABBV dated on 2018-07-17: UPDATE: Mylan Will Pay AbbVie For Licensing HUMIRA Patents Once Its Biosimilar Product Is Launched, No Terms Disclosed

Financial news for ABBV dated on 2018-07-17: UPDATE: Mylan's US License For HUMIRA Will Begin On Jul. 31, 2023 And Will Not Be Accelerated By Amgen, Samsung Bioepis Entry

Financial news for ABBV dated on 2018-07-17: UPDATE: AbbVie To Grant Mylan Non-Exclusive License On Specified Dates To AbbVie's Intellectual Property Related To HUMIRA In US, Various Other Countries, Excluding Europe

Financial news for ABBV dated on 2018-07-17: AbbVie Reports HUMIRA Patent License With Mylan

Financial news for ABBV dated on 2018-07-12: Berenberg Initiates Coverage On AbbVie with Hold Rating, Announces \$105 Price Target

Financial news for ABBV dated on 2018-07-12: AbbVie Announces Submission of sNDA to FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Financial news for ABBV dated on 2018-07-11: AbbVie Says The DBL3001 Study Did Not Show Additional Efficacy When Adding ibrutinib , But Clinically-Meaningful Response Was Observed In A Patient Sub-Population Warranting Further Analysis

Financial news for ABBV dated on 2018-07-05: U.S. Judge Overturns \$140M Verdict Against Abbvie In Lawsuit Over Androgel Risks

Financial news for ABBV dated on 2018-06-28: Argenx Receives \$10M Milestone Payment Under Development Agreement With AbbVie

Financial news for ABBV dated on 2018-06-26: AbbVie and Calico Announce 3-Year Extension of Collaboration To Focus On Aging And Age-Related Diseases

Financial news for ABBV dated on 2018-06-25: AbbVie and Scripps' Calibr Announce Collaboration for T-Cell Therapies Aimed at Cancer

Financial news for ABBV dated on 2018-06-21: AbbVie and Eisai Announce Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL

Financial news for ABBV dated on 2018-06-15: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic

Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at #EHA2018

Financial news for ABBV dated on 2018-06-13: AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in RA at EULAR 2018

Financial news for ABBV dated on 2018-06-11: Argus Maintains Buy on AbbVie, Lowers Price Target to \$130

Financial news for ABBV dated on 2018-06-11: AbbVie,d Eisai Announce Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA

Financial news for ABBV dated on 2018-06-08: FDA Wins Approval For AbbVie, Genentech's Venclexta For Treatment Of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Financial news for ABBV dated on 2018-06-05: Abbvie Announces Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

Financial news for ABBV dated on 2018-06-04: Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'

Financial news for ABBV dated on 2018-06-03: AbbVie AbbPhase 2 IMBRUVICA Plus VENCLEXTA Early Data Show High Rates of Responses in Patients with Previously-Untreated CLL at #ASCO2018

Financial news for ABBV dated on 2018-06-01: Abbvie Announces Phase 3 Data For IMBRUVICA Suggests Improved Treatment Outcomes In Waldenstrom's Macroglobulinemia

Financial news for ABBV dated on 2018-06-01: PiperJaffray Downgrades AbbVie to Neutral

Financial news for ABBV dated on 2018-05-30: AbbVie Announces Prelim. Results Of Modified Dutch Auction Tender; Total of 74,033,457 Shares Common Stock Tendered At/Bleow \$103/Share

Financial news for ABBV dated on 2018-05-30: AbbVie Tenders 75.74M Shars At \$105/Share

Financial news for ABBV dated on 2018-05-30: Credit Suisse Downgrades AbbVie to Underperform, Lowers Price Target to \$89

Financial news for ABBV dated on 2018-05-24: UPDATE: AbbVie Says IMBRUVICA Plus GAZYVA Full Study Results Could Support IMBRUVICA-Based Chemotherapy-Free Combo Treatment Option For Patients

Financial news for ABBV dated on 2018-05-24: AbbVie Reports IMBRUVICA Plus GAZYVA Phase 3 iLLUMINATE Trial For First-Line Therapy Of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint

Financial news for ABBV dated on 2018-05-01: AbbVie Reports Submission Of Marketing Authorization Application To EMA For Risankizumab For Moderate To Severe Plaque Psoriasis

Financial news for ABBV dated on 2018-05-01: AbbVie Reports Commencement Of Self-Tender Offer For Up To \$7.5B In Common Stock

Financial news for ABBV dated on 2018-04-30: Morgan Stanley Maintains Equal-Weight on AbbVie, Lowers Price Target to \$110.00

Financial news for ABBV dated on 2018-04-27: Credit Suisse Maintains Neutral on AbbVie, Lowers Price Target to \$104.00

Financial news for ABBV dated on 2018-04-26: Abbvie To Commence Tender Offer For Up To \$7.5B Of Common Stock Through Modified 'Dutch Auction' Tender Offer As Early As May 1, 2018

Financial news for ABBV dated on 2018-04-26: AbbVie Raises Guidance From \$7.33-\$7.43 To \$7.66-\$7.76

Financial news for ABBV dated on 2018-04-26: AbbVie Q1 EPS \$1.87 Beats \$1.79 Est., Sales \$7.93B Beats \$7.6B Est.

Financial news for ABBV dated on 2018-04-25: AbbVie Submits BLA Application To FDA for Risankizumab

Financial news for ABBV dated on 2018-04-25: AbbVie Reports Upadacitinib Met Primary, Key Efficacy Endpoints In Phase 2b/3 RA Study In Japanese Patients

Financial news for ABBV dated on 2018-04-09: AbbVie's Upadacitinib Met its Primary Endpoints

Financial news for ABBV dated on 2018-04-05: Barclays Maintains Equal-Weight on AbbVie, Lowers Price Target to \$102.00

Financial news for ABBV dated on 2018-04-05: AbbVie Reports Global Resolution Of HUMIRA Patent Disputes With Samsung Bioepis; Deal Provides Non-Exclusive License To Samsung Bioepis For HUMIRA-Related IP In US, Effective Jun. 30, Other Markets On Diff. Dates

Financial news for ABBV dated on 2018-04-05: Biogen, Samsung Bioepis Reach Deal With AbbVie For Commercialization Of IMRALDI In Europe

Financial news for ABBV dated on 2018-03-23: BMO Capital Maintains Underperform on AbbVie, Lowers Price Target to \$80.00

Financial news for ABBV dated on 2018-03-22: Abbvie Shares Down 13.7% After Co. Earlier Backed Away From Pursuing Early Approval Of Rova-T After Disappointing Study Data

Financial news for ABBV dated on 2018-03-22: AbbVie Shares Not Reacting Dramatically As Hearing Jefferies Out Negative On Outcome For Co.'s TRINITY Trial Could Impact Earnings By 4-5%

Financial news for ABBV dated on 2018-03-22: UPDATE: AbbVie Says Ongoing Phase 3 Studies, MERU, TAHOE, To Continue To Investigate Rova-T In 1st-, 2nd-Line SCLC

Financial news for ABBV dated on 2018-03-22: UPDATE: AbbVie Says Rova-T Showed Single Agent Responses In Advanced SCLC Patients

Financial news for ABBV dated on 2018-03-22: AbbVie Offers Results From Phase 2 Study Of Rova-T In 3rd-Line Treatment Of Patients With DLL3-Expressing Relapsed/Refractory SCLC: Will Not Seek Accelerated Approval

Financial news for ABBV dated on 2018-03-21: AbbVie, Int'l. Myeloma Foundation Report Partnership To Study Role Of Genetic Mutation In Outcomes Of Patients With Multiple Myeloma

Financial news for ABBV dated on 2018-03-13: AbbVie Announces its Phase 3 Study of Elagolix Met its Primary Endpoint and All Secondary Endpoints

Financial news for ABBV dated on 2018-03-02: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA for Relapsing Multiple Sclerosis

Financial news for ABBV dated on 2018-02-21: AbbVie Says the First Two Phase 3 Studies Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Primary Endpoints

Financial news for ABBV dated on 2018-02-20: Voyager Therapeutics to Collaborate with AbbVie on Treatments for Alzheimer's Disease, Voyager to Revive a \$69M Upfront Payment

Financial news for ABBV dated on 2018-02-16: UPDATE: AbbVie New Phase 2 Data On Upadacitinib 'overall safety profile of upadacitinib was consistent with that observed in other upadacitinib studies, with no new safety signals detected'

Financial news for ABBV dated on 2018-02-16: AbbVie Reports New Phase 2 Data For Upadacitinib For Clinical, Endoscopic Outcomes In Crohn's Disease: 'showed that many upadacitinib-treated patients who achieved clinical response'

Financial news for ABBV dated on 2018-02-15: Abbvie Opens, Now Up 1.96% At \$115.32/Share

Financial news for ABBV dated on 2018-02-15: Hearing Abbvie Indicated \$114.50-\$117.50

Financial news for ABBV dated on 2018-02-15: AbbVie Increases Qtr. Dividend From \$0.71 To \$0.96/Share

Financial news for ABBV dated on 2018-02-15: AbbVie Reports New \$10B Buyback Plan

Financial news for ABBV dated on 2018-02-15: BZ NOTE On Trading Halt In AbbVie: Co. Issued Press Release On Mon. Highlighting Will Showcase Investigational Data At AAD Meeting On Sat.

Financial news for ABBV dated on 2018-02-15: AbbVie Shares Halted News Pending

Financial news for ABBV dated on 2018-02-15: Gilead Shares Unaffected, AbbVie Shares Move Lower Amid Capitol Forum Report 'Rep. Khanna and Other Democrats Urge HHS to Take Patents, Pave Way for Cheaper HCV Generics'

Financial news for ABBV dated on 2018-02-02: Argus Maintains Buy on AbbVie, Raises Price Target to \$145.00

Financial news for ABBV dated on 2018-01-30: Morgan Stanley Maintains Equal-Weight on AbbVie, Raises Price Target to \$131.00

Financial news for ABBV dated on 2018-01-30: BMO Capital Downgrades AbbVie to Underperform

Financial news for ABBV dated on 2018-01-29: Credit Suisse Raises AbbVie Price Target From \$98 To \$135 On Stronger Than Expected Humana Growth And A Significantly Lowered Tax Rate From The U.S. Tax Cuts And Jobs Act

Financial news for ABBV dated on 2018-01-29: Leerink Swann Downgrades AbbVie to Market Perform

Financial news for ABBV dated on 2018-01-26: AbbVie Says Plans To Make Investments Of ~\$2.5B Over Next 5 Years In US Capital Projects

Financial news for ABBV dated on 2018-01-26: AbbVie Raises FY18 Adj. EPS Outlook From \$6.37-\$6.57 To \$7.33-\$7.43 vs \$6.59 Est.

Financial news for ABBV dated on 2018-01-26: AbbVie Reports Q4 Adj. EPS \$1.48 vs \$1.44 Est., Sales \$7.739B vs \$7.53B Est.

Financial news for ABBV dated on 2018-01-10: Abbvie CEO Says upadacitinb Immunocology Drug Can Reach \$6.5B In Sales By 2025 With 6 Indications

Financial news for ABBV dated on 2018-01-10: Abbvie CEO Plans To Advance Neuroscience Pipeline To Contribute To Sales Growth In The Coming Decade

Financial news for ABBV dated on 2018-01-08: AbbVie Earlier Announced FDA Granted Breakthrough Therapy Designation To ABT-494

Financial news for ABBV dated on 2017-12-22: The \$150M Verdict Against Abbvie for Androgel is Thrown Out

Financial news for ABBV dated on 2017-12-20: AbbVie Reports Upadacitinib Showed Positive Results As Monotherapy In Phase 3 RA Study, Met All Primary, Key Secondary Endpoints

Financial news for ABBV dated on 2017-12-14: STAT News' Adam Feuerstein Responds To Tweet Highlighting '\$PFE \$AGN rumor - no source': 'The other day I heard \$PFE for \$BMV,' 'Also \$ABBV for \$BMV'

Financial news for ABBV dated on 2017-12-12: AbbVie Reports Phase 3 Study Of VENCLEXTA/VENCLYXTO Combo with Rituxan Met Primary Endpoint

Financial news for ABBV dated on 2017-12-11: Abbvie Reports IMVRUVICA Clinical Results Suggest Drug Inhibits B Cells and Follicular Helper T-Cells That Are Thought To Play Crucial Role In Treating cGVHD, While Preserving Immune Memory and Th1 T Cells

Financial news for ABBV dated on 2017-12-05: AbbVie's INBRUVICA Plus Rituzimax Phase 3 INNOVATE Trial in Rare Waldenstrom's Macroglobulinemia Met its Primary Endpoint

Financial news for ABBV dated on 2017-12-04: AbbVie Reports Fourth Pivotal Phase 3 Psoriasis Study For Risankizumab Met All Primary Endpoints

Financial news for ABBV dated on 2017-11-30: Enanta Says AbbVie's MAVIRET Is Now Available In Japan For Treatment Of GT1-6

Financial news for ABBV dated on 2017-11-16: BMO Capital Maintains Market Perform on AbbVie, Raises Price Target to \$84.00

Financial news for ABBV dated on 2017-11-01: AbbVie Announces 'Positive' Phase 3 Extension Study Data For Elagolix

Financial news for ABBV dated on 2017-10-31: Adam Feuerstein Tweets: FDA approves \$AZN acalabrutinib for patients w/ mantle cell lymphoma. Brand name: Calquence. Recall, this is the "Imbruvica killer." \$ABBV

Financial news for ABBV dated on 2017-10-27: Abbvie CEO on Conf. Call Says It'd

Attempt To Get A Prelim. Injunction To Block Any Launches That Violate Humira IP

Financial news for ABBV dated on 2017-10-27: AbbVie Sees FY17 Adj. EPS \$5.33-\$5.55 vs \$5.53 Est., FY18 Adj. EPS \$6.37-\$6.57 vs \$6.56 Est.

Financial news for ABBV dated on 2017-10-27: AbbVie Reports Q3 Adj. EPS \$1.41 vs \$1.38 Est., Sales \$6.995B vs \$7B Est.

Financial news for ABBV dated on 2017-10-27: AbbVie Raises Qtr. Dividend From \$0.64 To \$0.71/Share

Financial news for ABBV dated on 2017-10-27: AbbVie Reports FDA Priority Review For Elagolix For Mgmt. Of Endometriosis With Associated Pain

Financial news for ABBV dated on 2017-10-26: AbbVie Reports Risankizumab Met All Co-Primary, Ranked Secondary Endpoints In 3 Pivotal Phase 3 Psoriasis Studies

Financial news for ABBV dated on 2017-10-24: Alektor and AbbVie Report Partnership to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease, Will Co-Fund Development and Commercialization And Will Share Global Profits Equally

Financial news for ABBV dated on 2017-10-19: AbbVie Shares Indicated Up 0.2% After Hours, Could Be Related To Celgene News Co. Discontinuing Crohn's Disease Drug Trial

Financial news for ABBV dated on 2017-10-18: AbbVie and Harpoon Therapeutics Report Immuno-Oncology Research Collaboration

Financial news for ABBV dated on 2017-10-11: Cowen & Co. Upgrades AbbVie to Outperform

Financial news for ABBV dated on 2017-10-10: AbbVie Reports Global Collaboration On Viral Immunotherapies In Oncology With Turnstone Biologics

Financial news for ABBV dated on 2017-10-02: Leerink Swann Upgrades AbbVie to Outperform

Financial news for ABBV dated on 2017-09-28: AbbVie Says 'Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates'

Financial news for ABBV dated on 2017-09-28: AbbVie Reports Resolution Of HUMIRA Patent Disputes With Amgen

Financial news for ABBV dated on 2017-09-27: AbbVie Shares Dip ~\$1 To Fresh Session Lows, Stock Down 2.2% For Session

Financial news for ABBV dated on 2017-09-27: Enanta Pharma Says AbbVie's MAVIRET Received Approval in Japan for Treatment of Chronic Hepatitis C

Financial news for ABBV dated on 2017-09-25: UBS Downgrades AbbVie to Neutral

Financial news for ABBV dated on 2017-09-22: AbbVie and Bristol-Myers Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors

Financial news for ABBV dated on 2017-09-18: Abbvie Trial Met Primary Endpoint In Phase 3 Trial For VENCLEXTA

Financial news for ABBV dated on 2017-09-11: AbbVie Reports ABT-494 Met All Primary, Ranked Secondary Endpoints In Second Phase 3 Trial For RA

Financial news for ABBV dated on 2017-09-07: AbbVie Shares Break To Session Highs After Clearing \$79, \$80, \$81, \$82 Technical Levels; Stock Up ~6% For Session

Financial news for ABBV dated on 2017-09-07: Coherus Shares Down ~\$0.45 Over Last Few Mins. As Traders Circulating Word AbbVie Prevailed Against Co. In IPR Patent Trial '619

Financial news for ABBV dated on 2017-09-06: AbbVie Reports Submission Of NDA For Investigational Oral Treatment Elagolix For Mgmt. Of Endometriosis With Associated Pain

Financial news for ABBV dated on 2017-08-17: Evercore ISI Group Initiates Coverage On AbbVie with Outperform Rating, Announces \$95.00 Price Target

Financial news for ABBV dated on 2017-08-14: 13F From Farallon Capital Shows New 835K Share Stake In AbbVie

Financial news for ABBV dated on 2017-08-03: Adam Feuerstein Tweets: \$GILD



competition. And \$ENTA gets a piece of Mavyret.

Financial news for ABBV dated on 2017-08-03: FDA Grants Approval For Abbvie's Mavyret For Hepatitis C

Financial news for ABBV dated on 2017-08-02: AbbVie Reports U.S. FDA Approves IMBRUVICA

Financial news for ABBV dated on 2017-07-28: Enanta To Receive \$25M Milestone Payment From AbbVie Following EU Marketing Authorization For MAVIRET

Financial news for ABBV dated on 2017-07-28: European Commission Grants AbbVie's MAVIRET Marketing Authorization

Financial news for ABBV dated on 2017-07-28: AbbVie Reaffirms FY17 Adj. EPS \$5.44-\$5.54 vs \$5.53 Est.

Financial news for ABBV dated on 2017-07-28: AbbVie Reports Q2 Adj. EPS \$1.42 vs \$1.40 Est., Sales \$6.944B vs \$6.93B Est.

Financial news for ABBV dated on 2017-07-21: AbbVie Receives CHMP Positive Opinion for HUMIRA

Financial news for ABBV dated on 2017-07-13: Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher

Financial news for ABBV dated on 2017-06-29: CytomX Therapeutics Reports Achieved Development Milestone In Strategic Oncology Collab With AbbVie For CD71-Targeting Probody Drug Conjugate

Financial news for ABBV dated on 2017-06-23: AbbVie Receives CHMP Positive Opinion for MAVIRET

Financial news for ABBV dated on 2017-06-23: EMA Recommends Approval For AbbVie's Hep C Combo

Financial news for ABBV dated on 2017-06-13: AbbVie, Principia Report Partnership on Oral Immunoproteasome Inhibitors, Terms Not Disclosed

Financial news for ABBV dated on 2017-06-08: Watch Regeneron, AbbVie and OncoSec as FDA Shows Orphan Status Granted

Financial news for ABBV dated on 2017-06-07: Synlogic Issues Release Highlighting Co. Met First Discovery Milestone in AbbVie Partnership

Financial news for ABBV dated on 2017-06-07: AbbVie Reports ABT-494 Met All Primary, Ranked Secondary Endpoints in Phase 3 Study in RA

Financial news for ABBV dated on 2017-05-22: UBS Global Health Care Conference Begins Today; Presenters Include: AbbVie, Aetna, Universal Health, Mylan, Community Health, Tenet Healthcare, & Bristol-Myers Squibb

Financial news for ABBV dated on 2017-05-17: AbbVie Issues Press Release Highlighting Presentation of Primary, Secondary Efficacy, Safety Data from Pivotal Phase 3 Trial of Elagolix at World Congress on Endometriosis

Financial news for ABBV dated on 2017-05-11: U.S. Health Officials Say New Cases Of Hep. C Rose ~300% From 2010 to 2015, Fueled By Spike In Heroin and Other Injection Drugs

Financial news for ABBV dated on 2017-05-09: AbbVie Reports Positive Phase 2 Study Results for Upadacitinib

Financial news for ABBV dated on 2017-05-05: Companies Holding Shareholder Meetings Today Include: AbbVie, Marriott International, MeetMe, TransCanada, & Tribune Media Company

Financial news for ABBV dated on 2017-05-03: Deutsche Bank Healthcare Conference Begins Today; Presenters Include Synergy Pharma, Exelixis, AbbVie, Collegium Pharma, Zimmer Biomet, Luminex, CRISPR Therapeutics, & Edwards Lifesciences

Financial news for ABBV dated on 2017-04-27: Abbvie CEO Says HCV Patient Volumes Still Trending Down Although At Slower Pace, He Thinks They Are Reaching Some Point Of Stability Going Forward

Financial news for ABBV dated on 2017-04-27: AbbVie Affirms FY17 Adj. EPS \$5.44-\$5.54 vs \$5.50 Est.

Financial news for ABBV dated on 2017-04-27: AbbVie Reports Q1 Adj. EPS \$1.28 vs

\$1.26 Est., Sales \$6.538B vs \$6.48B Est.

Financial news for ABBV dated on 2017-04-25: Aquinnah Pharma Reports Received \$10M Investment from Pfizer, AbbVie for Research Breakthrough Approach to Neurodegenerative Disease

Financial news for ABBV dated on 2017-04-21: Enanta Pharma Reports 8 Weeks of AbbVie's G/P Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients

Financial news for ABBV dated on 2017-04-20: AbbVie Says 'new data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic HCV infection with 12 weeks of treatment'

Financial news for ABBV dated on 2017-04-20: AbbVie Reports Regimen of Glecaprevir/Pibrentasvir Achieved 99% SVR Rate in Chronic Hep C Patients with Compensated Cirrhosis

Financial news for ABBV dated on 2017-04-19: Abbvie Shares Down 2.8% After 2 Trials of Veliparib did Not Meet Endpoints

Financial news for ABBV dated on 2017-04-07: AbbVie Reports Phase 2b Data Showing Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids

Financial news for ABBV dated on 2017-04-04: AbbVie Reports IMRUVICA sNDA for Previously-Treated cGVHD Accepted for FDA Review

Financial news for ABBV dated on 2017-03-30: AbbVie Reports FDA Approval of Addition to Moderate to Severe Fingernail Psoriasis Data to Co.'s HUMIRA Prescribing Information

Financial news for ABBV dated on 2017-03-28: AbbVie and M2Gen Report New Partnership For ORIEN Avatar Research Program

Financial news for ABBV dated on 2017-03-22: AbbVie Shares Up ~\$0.20 Over Last Min as Hearing SocGen Upgraded Stock to Hold

Financial news for ABBV dated on 2017-03-14: AbbVie Reports Granted Priority Review in Japan for Investigational Regimen of G/P for Treatment of All Major Genotypes of Chronic Hep C

Financial news for ABBV dated on 2017-03-10: Goldman Sachs Adds AbbVie to Conviction Buy List, Raises Price Target from \$74 to \$80.00

Financial news for ABBV dated on 2017-02-17: AbbVie Adds \$5B to Buyback Plan

Financial news for ABBV dated on 2017-02-02: AbbVie Reports FDA Granted Priority Review for Glecaprevir/Pibrentasvir for Treatment of Chronic Hep C in All GT1-6

Financial news for ABBV dated on 2017-01-27: Q4 2016 Real-Time Call Brief

Financial news for ABBV dated on 2017-01-27: AbbVie On Conf. Call Says It Expects Global Viekira Sales Of \$1B In FY17

Financial news for ABBV dated on 2017-01-27: AbbVie Says 2016 U.S. Sales OF Humira Grew More Than 24% With Mid-Teens Prescription Growth And Contribution From Price In High Single-Digits

Financial news for ABBV dated on 2017-01-27: AbbVie Sees FY17 Adj. EPS \$5.44-\$5.54 vs \$5.47 Est.

Financial news for ABBV dated on 2017-01-27: AbbVie Sees FY17 EPS \$5.44-\$5.54 vs. Est. \$5.47

Financial news for ABBV dated on 2017-01-27: Abbvie Reports Q4 EPS \$1.20 vs. Est. \$1.19, Rev. \$6.796B vs. Est. \$6.92B

Financial news for ABBV dated on 2017-01-25: AbbVie Begins Phase 2 Clinical Trial Programs for ABBV-8E12

Financial news for ABBV dated on 2017-01-19: U.S. FDA Approves IMBRUVICA as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma

Financial news for ABBV dated on 2017-01-11: Presenting At JPMorgan Healthcare Conf., Abbvie Says They See At Least 7 Drugs In Clinical Trials From Stemcentrx In 2017

Financial news for ABBV dated on 2017-01-11: AbbVie Presenting At JPMorgan Healthcare Conf., CEO Sees Annual Humira Exceeding Sales Of \$18B By 2020

Financial news for ABBV dated on 2017-01-11: Abbvie Sees FY17 Adj. EPS Growth Of 13-15%

Financial news for ABBV dated on 2017-01-09: AbbVie and Pure PMC Partner for Oncology Research

Financial news for ABBV dated on 2017-01-04: Abbvie Also Mentioned Positively On CNBC By Najarians

Financial news for ABBV dated on 2016-11-28: Citigroup Downgrades AbbVie to Neutral

Financial news for ABBV dated on 2016-10-31: Credit Suisse Downgrades AbbVie Inc. Common Stock to Neutral

Financial news for ABBV dated on 2016-10-18: Leerink Swann Initiates Coverage On AbbVie Inc. Common Stock at Market Perform

Financial news for ABBV dated on 2016-09-08: JP Morgan Downgrades AbbVie to Neutral

Financial news for ABBV dated on 2016-09-02: Raymond James Initiates Coverage on AbbVie at Outperform, Announces \$82.00 PT

Financial news for ABBV dated on 2016-06-10: BMO Capital Downgrades AbbVie to Market Perform

Financial news for ABBV dated on 2016-06-08: Morgan Stanley Downgrades AbbVie to Equal-weight, Lowers PT to \$65.00

Financial news for ABBV dated on 2016-06-06: Cowen & Company Downgrades AbbVie to Market Perform

Financial news for ABBV dated on 2016-04-06: Societe Generale Initiates Coverage on AbbVie at Sell

Financial news for ABBV dated on 2016-03-15: Deutsche Bank Initiates Coverage on AbbVie at Hold, Announces \$63.00 PT

Financial news for ABBV dated on 2016-02-23: Citigroup Upgrades AbbVie to Buy, Raises PT to \$65.00

Financial news for ABBV dated on 2016-02-05: William Blair Initiates Coverage on AbbVie at Outperform

Financial news for ABBV dated on 2016-01-28: Abbvie Announces Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA

Financial news for ABBV dated on 2015-12-18: Atlantic Equities Initiates Coverage on AbbVie at Neutral, Announces \$59.00 PT

Financial news for ABBV dated on 2015-12-06: AbbVie Announces NEJM Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2015-12-06: AbbVie Announces Ibrutinib Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma

Financial news for ABBV dated on 2015-12-01: Barclays Downgrades AbbVie to Equal-weight, Lowers PT to \$72.00

Financial news for ABBV dated on 2015-11-02: Morgan Stanley Upgrades AbbVie to Overweight, Announces \$73.00 PT

Financial news for ABBV dated on 2015-09-28: Correction: Citigroup Upgrades AbbVie to Neutral, Raises PT to \$60.00

Financial news for ABBV dated on 2015-09-28: AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

Financial news for ABBV dated on 2015-07-29: Deutsche Bank Maintains Buy on AbbVie, Raises PT to \$85.00

Financial news for ABBV dated on 2015-07-22: SunTrust Robinson Humphrey Initiates Coverage on AbbVie at Buy, Announces \$85.00 PT

Financial news for ABBV dated on 2015-07-10: AbbVie Reports IMBRUIVCA Now Approved to Treat Waldenstrom's Macroglobulinemia in Europe

Financial news for ABBV dated on 2015-06-16: Piper Jaffray Initiates Coverage on AbbVie at Overweight

Financial news for ABBV dated on 2015-06-15: AbbVie, Galapagos Present Cystic Fibrosis Corrector and Potentiator Screening Approach at ECFS Conference

Financial news for ABBV dated on 2015-06-12: Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory CLL

Financial news for ABBV dated on 2015-06-08: Jefferies Maintains Buy on AbbVie, Raises PT to \$90.00

Financial news for ABBV dated on 2015-06-08: Jefferies Maintains Buy on AbbVie, Lowers PT to \$90.00

Financial news for ABBV dated on 2015-05-31: Pharmacoclics Announces IMBRUVICA Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease at ASCO

Financial news for ABBV dated on 2015-05-31: Analysis of Phase III RESONATE Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA(r) (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia

Financial news for ABBV dated on 2015-05-31: AbbVie Presents Positive Results from Phase 1 Studies of Venetoclax in Patients with Multiple Myeloma at ASCO

Financial news for ABBV dated on 2015-05-30: Phase III HELIOS Study Results Show IMBRUVICA Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

Financial news for ABBV dated on 2015-05-28: Morgan Stanley Assumes AbbVie at Equal-weight, Announces \$72.00 PT

Financial news for ABBV dated on 2015-05-27: JP Morgan Reinstates Outperform on AbbVie, Announces \$75.00 PT

Financial news for ABBV dated on 2015-05-26: AbbVie Announces Primary, Secondary Endpoints Met for Investigational Hep C Treatment in Japanese Patients Without Cirrhosis

Financial news for ABBV dated on 2015-05-26: Enanta Announces 95% SVR12 Results from AbbVie GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hep C Virus1

Financial news for ABBV dated on 2015-04-25: AbbVie Presents Preliminary Phase 3b Data with VIEKIRAX + EXVIERA in Chronic Hep C Patients with Renal Impairment at ILC 2015

Financial news for ABBV dated on 2015-04-24: FDA Accepts NDA, Grants Priority Review to AbbVie for OBV/PTV/r With RBV

Financial news for ABBV dated on 2015-04-15: Enanta Pharmaceuticals Announces AbbVie's Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan

Financial news for ABBV dated on 2015-04-13: BMO Capital Upgrades AbbVie to Outperform, Raises PT to \$68.00

Financial news for ABBV dated on 2015-03-27: Biogen, AbbVie Announce EMA Validates Marketing Authorisation Application for ZINBRYTA for Treatment of MS

Financial news for ABBV dated on 2015-03-05: AbbVie to Acquire Pharmacoclics for \$261.25/Share in Cash, Stock

Financial news for ABBV dated on 2015-02-12: AbbVie Submits NDA in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

Financial news for ABBV dated on 2015-02-09: Citigroup Initiates Coverage on AbbVie at Sell, Announces \$48.00 PT

Financial news for ABBV dated on 2015-01-16: EC Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA for Treatment of Chronic Hepatitis C

Financial news for ABBV dated on 2015-01-08: UPDATE: AbbVie Sees FY2015 EPS \$4.25-4.45 vs \$4.42 Est

Financial news for ABBV dated on 2014-12-22: Enanta Announces FDA Approval for AbbVie's VIEKIRA PAK

Financial news for ABBV dated on 2014-12-19: Galapagos initiates First Phase 1 Study With GLPG1837, to Receive \$10M Milestone Payment from AbbVie

Financial news for ABBV dated on 2014-12-07: AbbVie Presents Results from Phase 2 Study of Venetoclax in Acute Myelogenous Leukemia at ASH Annual Meeting

Financial news for ABBV dated on 2014-12-04: Jefferies Maintains Buy on AbbVie, Raises PT to \$80.00

Financial news for ABBV dated on 2014-11-14: Deutsche Bank Initiates Coverage on AbbVie at Buy, Announces \$80.00 PT

Financial news for ABBV dated on 2014-10-31: AbbVie Raises FY2014 EPS Guidance from \$3.06-3.16 to \$3.25-3.27 vs \$3.16 Est

Financial news for ABBV dated on 2014-10-31: AbbVie Reports Q3 EPS of \$0.89 vs \$0.77 Est; Revenue of \$5.02B vs \$4.82B Est

Financial news for ABBV dated on 2014-10-17: ISI Group Initiates Coverage on AbbVie at Buy, Announces \$58.00 PT

Financial news for ABBV dated on 2014-10-16: AbbVie Board Recommends Shareholders Vote Against Shire Transaction

Financial news for ABBV dated on 2014-10-02: Guggenheim Securities Initiates Coverage on AbbVie at Buy, Announces \$70.00 PT

Financial news for ABBV dated on 2014-09-11: AbbVie Announces Phase 3 Trial Evaluating Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa Met Primary Endpoint

Financial news for ABBV dated on 2014-09-03: AbbVie, Calico Announce Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies

Financial news for ABBV dated on 2014-09-03: Infinity, AbbVie Enter Global Strategic Collaboration to Develop and Commercialize Duvelisib In Oncology

Financial news for ABBV dated on 2014-07-28: UBS Upgrades AbbVie to Buy, Raises PT to \$67.00

Financial news for ABBV dated on 2014-07-25: AbbVie Sees Q3 EPS \$0.77-0.79 vs \$0.77 Est

Financial news for ABBV dated on 2014-07-25: AbbVie Reports Q2 EPS of \$0.82 vs \$0.76 Est; Revenue of \$4.93B vs \$4.70B Est; Reaffirms Outlook

Financial news for ABBV dated on 2014-07-18: Jefferies Maintains Buy on AbbVie, Raises PT to \$85.00

Financial news for ABBV dated on 2014-07-02: Barclays Upgrades AbbVie to Overweight, Raises PT to \$69.00

Financial news for ABBV dated on 2014-06-23: AbbVie Sees FY2014 EPS \$3.06-3.16 vs \$3.14 Est

Financial news for ABBV dated on 2014-06-20: Shire Rejects AbbVie Proposal

Financial news for ABBV dated on 2014-06-11: AbbVie Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy

Financial news for ABBV dated on 2014-05-31: AbbVie Presents Interim Results from Studies of Investigational Oncology Compound ABT-199/GDC-0199 at ASCO

Financial news for ABBV dated on 2014-05-07: Morgan Stanley Upgrades AbbVie to Overweight, Raises PT to \$60.00

Financial news for ABBV dated on 2014-04-25: AbbVie Reports Q1 EPS of \$0.71 vs \$0.68 Est; Revenue of \$4.56B vs \$4.33B Est

Financial news for ABBV dated on 2014-04-24: Bank of America Maintains Buy on AbbVie, Lowers PO to \$55.00

Financial news for ABBV dated on 2014-04-11: AbbVie to Present Detailed Phase III Results from SAPPHERE-I and SAPPHERE-II Studies in Chronic Hepatitis C Patients at ILC 2014

Financial news for ABBV dated on 2014-03-24: AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at ILC

Financial news for ABBV dated on 2014-02-21: Bank of America Maintains Buy on AbbVie, Raises PO to \$58.00

Financial news for ABBV dated on 2014-02-05: AbbVie Invests \$320M in Singapore

Financial news for ABBV dated on 2014-01-31: AbbVie Sees FY2013 EPS \$3.00-3.10 vs \$3.13 Est

Financial news for ABBV dated on 2014-01-31: AbbVie Reports Q4 EPS of \$0.82, Inline; Revenue of \$5.11B vs \$5.10B Est

Financial news for ABBV dated on 2014-01-27: Morgan Stanley Maintains Equal-weight on AbbVie, Lowers PT to \$47.00

Financial news for ABBV dated on 2014-01-15: AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage Triple-Negative Breast Cancer

Financial news for ABBV dated on 2013-12-31: Bank of America Maintains Buy on AbbVie, Raises PO to \$56.00

Financial news for ABBV dated on 2013-12-19: Morgan Stanley Downgrades AbbVie to Equal-weight, Maintains \$57.00 PT

Financial news for ABBV dated on 2013-11-03: Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting

Financial news for ABBV dated on 2013-10-25: AbbVie Sees FY2013 EPS \$3.11-3.13 vs \$3.13 Est

Financial news for ABBV dated on 2013-10-03: AbbVie Presents Phase II Data for HUMIRA in HS Patients

Financial news for ABBV dated on 2013-10-01: AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting

Financial news for ABBV dated on 2013-08-12: Argus Research Initiates Coverage on AbbVie at Buy, Announces \$52.00 PT

Financial news for ABBV dated on 2013-07-26: AbbVie Raises FY2013 EPS Guidance from \$3.03-3.13 to \$3.07-3.13 vs \$3.11 Est

Financial news for ABBV dated on 2013-07-26: AbbVie Reports Q2 EPS of \$0.82 vs \$0.79 Est; Revenue of \$4.69B vs \$4.54B Est

Financial news for ABBV dated on 2013-06-15: Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study

Financial news for ABBV dated on 2013-06-13: AbbVie Announces Positive Results from Concerto Trial

Financial news for ABBV dated on 2013-06-07: Jefferies Maintains Buy on AbbVie, Lowers PT to \$51.00

Financial news for ABBV dated on 2013-05-28: Jefferies Maintains Buy on AbbVie, Raises PT to \$54.00

Financial news for ABBV dated on 2013-05-15: Cowen & Company Initiates Coverage on AbbVie at Outperform

Financial news for ABBV dated on 2013-04-29: BMO Capital Maintains Market Perform on AbbVie, Raises PT to \$47.00

Financial news for ABBV dated on 2013-04-26: AbbVie Reports FY EPS of \$0.68 vs \$0.67 Est

Financial news for ABBV dated on 2013-04-22: Morgan Stanley Upgrades AbbVie to Overweight, Raises PT to \$49.00

Financial news for ABBV dated on 2013-04-10: UBS Maintains Neutral on AbbVie, Raises PT to \$40.00

Financial news for ABBV dated on 2013-04-10: Jefferies Maintains Buy on AbbVie, Raises PT to \$50.00

Financial news for ABBV dated on 2013-04-09: Goldman Sachs Maintains Buy on AbbVie, Raises PT to \$45.00

Financial news for ABBV dated on 2013-04-05: BMO Capital Maintains Market Perform on AbbVie, Raises PT to \$43.00

Financial news for ABBV dated on 2013-04-01: BMO Capital Downgrades AbbVie to Market Perform, Raises PT to \$42.00

Financial news for ABBV dated on 2013-03-11: Bank of America Maintains Buy on AbbVie, Raises PO to \$42.00

Financial news for ABBV dated on 2013-02-15: AbbVie Announces \$1.5B Buyback Plan, Declares \$0.40/Share Dividend

Financial news for ABBV dated on 2013-02-07: UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Financial news for ABBV dated on 2013-02-05: Perrigo Confirms FDA Approval for Generic AbbVie Product

Financial news for ABBV dated on 2013-02-04: UPDATE: Jefferies Raises PT to \$45 on AbbVie on Pipeline Visibility

Financial news for ABBV dated on 2013-01-30: AbbVie Says Not Planning Major Share Buybacks; Best Way to Deliver Value is to Boost Dividend

Financial news for ABBV dated on 2013-01-30: AbbVie Sees Q1 Adj-EPS \$0.64-0.66 vs \$0.69 Est

Financial news for ABBV dated on 2013-01-30: AbbVie Sees FY2013 EPS \$3.03-3.13 vs \$3.08 Est

Financial news for ABBV dated on 2013-01-16: UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Financial news for ABBV dated on 2013-01-16: Benzinga's Top Initiations

Financial news for ABBV dated on 2013-01-07: US Stock Futures Edge Lower; Euro Drops Versus Dollar

Financial news for ABBV dated on 2013-01-07: Stocks To Watch For January 7, 2013

Financial news for ABBV dated on 2013-01-04: AbbVie Declares Inaugural Dividend of \$0.40/Share

Financial news for ABBV dated on 2013-01-04: AbbVie Declares First-Ever Qtr. Dividend, \$0.40/Share

Financial news for ABBV dated on 2013-01-04: UPDATE: Bank of America Merrill Lynch Initiates Coverage on AbbVie with Buy Rating, \$40 PT

Financial news for ABBV dated on 2013-01-03: UPDATE: Morgan Stanley Initiates AbbVie at Equal-Weight; Heavy Reliance on Humira

Financial news for ABBV dated on 2013-01-03: Three Actionable Trading Ideas Right Now

Financial news for ABBV dated on 2013-01-02: UPDATE: BMO Capital Markets Initiates AbbVie at Outperform on Yield, Humira Support

Financial news for ABBV dated on 2013-01-02: Abbott Spin-Off AbbVie Open for Trade, Shares Now Around \$34.70

Financial news for ABBV dated on 2013-01-02: UPDATE: J.P. Morgan Initiates Coverage on AbbVie with Neutral Rating, \$38 PT